TWD 75.9
(0.0%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 195.03 Million TWD | -35.31% |
2022 | 301.5 Million TWD | 33.39% |
2021 | 226.02 Million TWD | -1.91% |
2020 | 230.43 Million TWD | 206.44% |
2019 | 75.19 Million TWD | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q1 | 103.85 Million TWD | 51.79% |
2024 Q2 | 94.18 Million TWD | -9.31% |
2023 Q4 | 68.42 Million TWD | 12.68% |
2023 FY | 195.03 Million TWD | -35.31% |
2023 Q3 | 60.72 Million TWD | 61.98% |
2023 Q2 | 37.48 Million TWD | 31.97% |
2023 Q1 | 28.4 Million TWD | 191.16% |
2022 FY | 301.5 Million TWD | 33.39% |
2022 Q4 | 9.75 Million TWD | 0.0% |
2021 FY | 226.02 Million TWD | -1.91% |
2020 FY | 230.43 Million TWD | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Allied Biotech Corporation | 720.43 Million TWD | 72.928% |
GeneFerm Biotechnology Co., Ltd. | 793.77 Million TWD | 75.429% |
Easywell Biomedicals, Inc. | 271.62 Million TWD | 28.197% |
TTY Biopharm Company Limited | 5.5 Billion TWD | 96.457% |
Synmosa Biopharma Corporation | 5.14 Billion TWD | 96.206% |
Orient EuroPharma Co., Ltd. | 4.59 Billion TWD | 95.753% |
Center Laboratories, Inc. | 1.39 Billion TWD | 86.009% |
Tien Liang BioTech Co., Ltd. | 459.99 Million TWD | 57.6% |
Orient Pharma Co., Ltd. | 889.91 Million TWD | 78.083% |
InnoPharmax Inc. | 46.07 Million TWD | -323.324% |
Johnson Chemical Pharmaceutical Works Co., Ltd. | 606.71 Million TWD | 67.853% |
Excelsior Biopharma Inc. | 771.56 Million TWD | 74.722% |
DV Biomed Co., Ltd. | 1.53 Billion TWD | 87.322% |
Handa Pharmaceuticals, Inc. | 1.1 Billion TWD | 82.371% |
UniPharma Co., Ltd. | 103.22 Million TWD | -88.95% |
Anxo Pharmaceutical Co., Ltd. | 939.94 Million TWD | 79.25% |
Alar Pharmaceuticals Inc. | 469.27 Million TWD | 58.438% |
Winston Medical Supply Co., Ltd. | 709.07 Million TWD | 72.494% |
Mercury Biopharmaceutical Corporation | 1.03 Million TWD | -18780.736% |
Bioray Biotech Co., Ltd | 191.83 Million TWD | -1.672% |
TSH Biopharm Corporation Limited | 810.91 Million TWD | 75.948% |